Online inquiry

IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6121MR)

This product GTTS-WQ6121MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Anemia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6121MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6658MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DI-17E6
GTTS-WQ8430MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ2001MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ12378MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NEOD-001
GTTS-WQ11079MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ11624MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ13116MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ1556MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-041
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW